FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2145298081> ?p ?o ?g. }

• W2145298081 endingPage "1233" @default.
• W2145298081 startingPage "1219" @default.
• W2145298081 abstract "Abstract The dismal prognosis of glioblastoma (GB) indicates the urgent need for new therapies for these tumors. Heat shock protein 90 (HSP90) inhibitors induce the proteasome-mediated degradation of many oncogenic client proteins involved in all of the hallmark characteristics of cancer. Here, we explored the mechanistic potential of the potent synthetic diarylisoxazole amide resorcinol HSP90 inhibitor, NVP-AUY922, in adult and pediatric GB. In vitro antiproliferative potency (nanomolar range) was seen in both adult and pediatric human GB cell lines with different molecular pathologies. A cytostatic effect was observed in all GB lines; more apoptosis was observed at lower concentrations in the SF188 pediatric GB line and at 144 hours in the slower growing KNS42 pediatric GB line, as compared with the adult GB lines U87MG and SF268. In vitro combination studies with inhibitors of phosphoinositide 3-kinase/mammalian target of rapamycin (PI-103) or mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (PD-0325901) supported the hypothesis that sustained inhibition of ERK up to 72 hours and at least temporary inhibition of AKT were necessary to induce apoptosis in GB lines. In athymic mice bearing established s.c U87MG GB xenografts, NVP-AUY922 (50 mg/kg i.p × 3 days) caused the inhibition of ERK1/2 and AKT phosphorylation and induced apoptosis, whereas 17-AAG used at maximum tolerated dose was less effective. NVP-AUY922 antitumor activity with objective tumor regression resulted from antiproliferative, proapoptotic, and antiangiogenic effects, the latter shown by decreased microvessel density and HIF1α levels. Our results have established a mechanistic proof of concept for the potential of novel synthetic HSP90 inhibitors in adult and pediatric GB, alone or in combination with phosphoinositide 3-kinase/mammalian target of rapamycin and mitogen-activated protein/ERK kinase inhibitors. Mol Cancer Ther; 9(5); 1219–33. ©2010 AACR." @default.
• W2145298081 created "2016-06-24" @default.
• W2145298081 creator A5003965204 @default.
• W2145298081 creator A5016790809 @default.
• W2145298081 creator A5019593377 @default.
• W2145298081 creator A5025972115 @default.
• W2145298081 creator A5031621086 @default.
• W2145298081 creator A5052706160 @default.
• W2145298081 creator A5062715691 @default.
• W2145298081 creator A5067202962 @default.
• W2145298081 creator A5075096091 @default.
• W2145298081 date "2010-05-01" @default.
• W2145298081 modified "2023-09-25" @default.
• W2145298081 title "Mechanistic Evaluation of the Novel HSP90 Inhibitor NVP-AUY922 in Adult and Pediatric Glioblastoma" @default.
• W2145298081 cites W1508849983 @default.
• W2145298081 cites W1966803171 @default.
• W2145298081 cites W1966956946 @default.
• W2145298081 cites W1970700441 @default.
• W2145298081 cites W1988036808 @default.
• W2145298081 cites W1997773537 @default.
• W2145298081 cites W1998863708 @default.
• W2145298081 cites W1999715990 @default.
• W2145298081 cites W2006389328 @default.
• W2145298081 cites W2009584325 @default.
• W2145298081 cites W2009914246 @default.
• W2145298081 cites W2012172048 @default.
• W2145298081 cites W2012520981 @default.
• W2145298081 cites W2015121790 @default.
• W2145298081 cites W2017709634 @default.
• W2145298081 cites W2030733656 @default.
• W2145298081 cites W2042985720 @default.
• W2145298081 cites W2044304089 @default.
• W2145298081 cites W2045436471 @default.
• W2145298081 cites W2053223343 @default.
• W2145298081 cites W2054485871 @default.
• W2145298081 cites W2070705072 @default.
• W2145298081 cites W2088326198 @default.
• W2145298081 cites W2097490615 @default.
• W2145298081 cites W2100288953 @default.
• W2145298081 cites W2103562758 @default.
• W2145298081 cites W2107055927 @default.
• W2145298081 cites W2112417555 @default.
• W2145298081 cites W2117627272 @default.
• W2145298081 cites W2124301570 @default.
• W2145298081 cites W2134749269 @default.
• W2145298081 cites W2136390065 @default.
• W2145298081 cites W2138549910 @default.
• W2145298081 cites W2145251502 @default.
• W2145298081 cites W2148584610 @default.
• W2145298081 cites W2155880350 @default.
• W2145298081 cites W2158681922 @default.
• W2145298081 cites W2162107265 @default.
• W2145298081 cites W2166999544 @default.
• W2145298081 cites W2167041673 @default.
• W2145298081 cites W2167852241 @default.
• W2145298081 cites W2168267246 @default.
• W2145298081 cites W2169908182 @default.
• W2145298081 cites W2170449714 @default.
• W2145298081 cites W2479044294 @default.
• W2145298081 doi "https://doi.org/10.1158/1535-7163.mct-09-0683" @default.
• W2145298081 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2875164" @default.
• W2145298081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20457619" @default.
• W2145298081 hasPublicationYear "2010" @default.
• W2145298081 type Work @default.
• W2145298081 sameAs 2145298081 @default.
• W2145298081 citedByCount "75" @default.
• W2145298081 countsByYear W21452980812012 @default.
• W2145298081 countsByYear W21452980812013 @default.
• W2145298081 countsByYear W21452980812014 @default.
• W2145298081 countsByYear W21452980812015 @default.
• W2145298081 countsByYear W21452980812016 @default.
• W2145298081 countsByYear W21452980812017 @default.
• W2145298081 countsByYear W21452980812018 @default.
• W2145298081 countsByYear W21452980812019 @default.
• W2145298081 countsByYear W21452980812020 @default.
• W2145298081 countsByYear W21452980812021 @default.
• W2145298081 countsByYear W21452980812022 @default.
• W2145298081 countsByYear W21452980812023 @default.
• W2145298081 crossrefType "journal-article" @default.
• W2145298081 hasAuthorship W2145298081A5003965204 @default.
• W2145298081 hasAuthorship W2145298081A5016790809 @default.
• W2145298081 hasAuthorship W2145298081A5019593377 @default.
• W2145298081 hasAuthorship W2145298081A5025972115 @default.
• W2145298081 hasAuthorship W2145298081A5031621086 @default.
• W2145298081 hasAuthorship W2145298081A5052706160 @default.
• W2145298081 hasAuthorship W2145298081A5062715691 @default.
• W2145298081 hasAuthorship W2145298081A5067202962 @default.
• W2145298081 hasAuthorship W2145298081A5075096091 @default.
• W2145298081 hasBestOaLocation W21452980811 @default.
• W2145298081 hasConcept C104317684 @default.
• W2145298081 hasConcept C153911025 @default.
• W2145298081 hasConcept C184235292 @default.
• W2145298081 hasConcept C185592680 @default.
• W2145298081 hasConcept C190283241 @default.
• W2145298081 hasConcept C205260736 @default.
• W2145298081 hasConcept C2775932338 @default.
• W2145298081 hasConcept C2777560012 @default.
• W2145298081 hasConcept C502942594 @default.

• next